A compound or composition for resisting persister bacteria and biofilm bacteria and its use
By developing the Clinfloxacin derivative cedafloxacin and its composition, the problem of difficulty in clearing surviving bacteria and biofilm bacteria in urinary tract infection is solved, and more effective treatment of urinary tract infection is achieved, especially in mouse models. Persistent infection removal effect.
Patent Information
- Application Number
- CN202210605897.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-05-30
AI Technical Summary
Existing antibiotic treatments are difficult to effectively remove surviving bacteria and biofilm bacteria present in urinary tract infections, making it difficult to treat recurrent urinary tract infections.
A clinfloxacin derivative cindafloxacin (QDF) and its compositions, including QDF, gentamicin and nitrofurantoin, were developed to combat sterilized and biofilm bacteria in vitro and mouse models by synthesis of 8 Clinfloxacin derivatives are extracted and their structure is optimized to improve antibacterial activity.
Cindafloxacin (QDF) + gentamicin + nitrofurantoin compositions show stronger bactericidal activity in vitro and mouse urinary tract infection models, and can completely eliminate sterile and biofilm bacteria, surpassing existing quinolones The effects of drugs such as levofloxacin and moxifloxacin provide a more effective treatment plan for recurrent urinary tract infection.
Smart Images

Figure CN114989165B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibiotics, and in particular to a drug compound or composition for resisting persister bacteria and biofilm bacteria and use thereof. Background Art
[0002] Urinary tract infections (UTIs) are common bacterial infections that infect any part of the urinary tract (urethra, bladder, or kidneys). Approximately 80% of UTIs are caused by uropathogenic Escherichia coli (UPEC). UTIs are more common in women than men, and it is estimated that 60% of women will have at least one UTI in their lifetime, with recurrences. Recurrent UTIs (RUTIs), defined as 2 UTIs within 6 months or 3 or more UTIs within 12 months, are the leading cause of UTI morbidity. Despite antibiotic treatment, more than 30% of women may be reinfected within 1 year after the initial symptoms resolve.
[0003] Up to 68% of recurrent UTIs are caused by the same strain of E. coli as the original strain. Common antibiotics used to treat UTIs include nitrofurantoin, sulfonamides (cotrimoxazole), fosfomycin, fluoroquinolones and beta-lactam antibiotics, and aminoglycosides. UTIs are becoming increasingly difficult to treat due to the drug resistance of UPEC.
[0004] UPEC can reach the bladder through the urethra, where the bacteria bind to bladder epithelial cells to evade host cell excretion. Once inside the cytoplasm of bladder epithelial cells, UPECs can form intracellular biofilm-like structures called intracellular bacterial communities (IBCs), which protect the bacteria from antibiotic treatment and clearance by the host immune system. Late in infection, when IBCs are fully mature, UPEC become filamentous and flow out of bladder epithelial cells, infiltrate other cells deep in the bladder, and undergo a cycle of entry-exit-reentry into quiescent intracellular reservoirs (QIRs), which can cause recurrent infections after antibiotic treatment. IBCs and QIRs as biofilms increase the difficulty of curing recurrent UTIs due to the presence of persistent bacteria.
[0005] Persisters are dormant cells that maintain a low metabolic state and exhibit multidrug resistance. When bacterial cultures are exposed to bactericidal antibiotics, although a large number of bacteria are killed, a small number of dormant bacteria called persisters survive. After the antibiotic is removed, the persisters resume growth, remain sensitive to the same antibiotics, and become the basis for recurrent persistent infections. The Yin-Yang model is proposed to describe the heterogeneity of persistent bacteria and develop more effective treatments for persistent infections by targeting non-growing persistent bacteria and growing bacteria. Using this principle, we previously found that the combination can effectively and completely eradicate persistent bacteria, including biofilm bacteria, and eliminate some persistent infections. According to the above Yin-Yang model, the combined use of antibiotics that are effective against growing bacterial populations (yang) and persistent bacteria (yin) can more effectively treat chronic infections and prevent recurrent infections; studies have shown that for Borrelia burgdorferi, the pathogen of Lyme disease, doxycycline alone cannot eradicate the biofilm-like microcolony form of bacteria, while the persister combination daptomycin + cefuroxime + doxycycline can eradicate all persister forms in vitro and in vivo in a mouse model. In addition, we previously found that clinafloxacin has some unique anti-persistent effects that are superior to many other quinolones, such as levofloxacin and moxifloxacin, and in combination can completely eradicate Staphylococcus aureus biofilm bacteria and Pseudomonas aeruginosa biofilm bacteria in vitro and in mice. In addition, our previous studies have shown that clinafloxacin has strong activity against uropathogenic Escherichia coli in vitro. However, due to the phototoxicity of clinafloxacin, it is not currently used clinically. Summary of the invention
[0006] The present invention aims to provide a compound or composition for resisting persister bacteria and its use. We first synthesized 8 clinafloxacin analogs, and found that compound 2, namely qingdashaxing (QDF), has stronger bactericidal activity than clinafloxacin through in vitro bactericidal experiments and experiments on killing persister bacteria. In the composition study, QDF+gentamicin+nitrofurantoin has the best activity against persister bacteria and biofilm bacteria in vitro and in a mouse urinary tract infection model, and can completely eliminate persister bacteria and biofilm bacteria and persistent infection, while quinolone drugs currently used in clinical practice, such as levofloxacin and moxifloxacin, cannot. "
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] A compound having anti-persistent bacteria and biofilm bacteria activity, wherein the compound is a clinafloxacin derivative selected from:
[0009]
[0010] Specifically, the The preparation raw materials include 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and 3-(tert-butoxycarbonylamino)pyrrolidine.
[0011] Specifically, the The preparation raw materials include 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester and 3-(tert-butoxycarbonylamino)pyrrolidine.
[0012] A composition having anti-persistent bacteria and biofilm bacteria properties, the composition comprising
[0013]
[0014] Any one or more of .
[0015] Specifically, the composition further comprises one and / or more of levofloxacin, nitrofurantoin, and gentamicin.
[0016] Specifically, the composition includes and gentamicin.
[0017] Specifically, the and gentamicin in an amount such that after administration of the composition and gentamicin to achieve the same blood concentration.
[0018] Specifically, the composition includes Nitrofurantoin and gentamicin.
[0019] Specifically, the Nitrofurantoin and gentamicin after administration of the combination Nitrofurantoin and gentamicin achieve similar plasma concentrations.
[0020] Use of a compound having the ability to resist persister bacteria and biofilm bacteria in the preparation of a drug capable of resisting persistent infection caused by Escherichia coli biofilm and / or persister bacteria of Escherichia coli biofilm, the compound comprising Any one or more of .
[0021] Specifically, the compound is used to treat urinary tract infection caused by uropathogenic Escherichia coli.
[0022] Specifically, the urinary tract infection includes recurrent and refractory urinary tract infection, as well as other chronic persistent infections and biofilm infections caused by Escherichia coli.
[0023] Specifically, the uropathogenic Escherichia coli includes Escherichia coli persisters.
[0024] A use of a composition having the ability to resist persister bacteria and biofilm bacteria in the preparation of a drug capable of resisting persistent infection caused by Escherichia coli biofilm and / or persister bacteria of Escherichia coli biofilm, wherein the composition comprises one or more of the above-mentioned compositions of claim 1.
[0025] Specifically, the composition is used to treat urinary tract infection caused by uropathogenic Escherichia coli.
[0026] Specifically, the urinary tract infection includes recurrent and refractory urinary tract infection, as well as other chronic persistent infections and biofilm infections caused by Escherichia coli.
[0027] Technical effects and advantages of the present invention:
[0028] QDF has stronger anti-persistent bacteria activity than the commonly used quinolone antibiotics in clinical practice, such as levofloxacin and moxifloxacin. In the combination study, QDF+gentamicin+nitrofurantoin has the best activity against non-growing stable bacteria and biofilm bacteria in vitro and in the mouse urinary tract infection model, and can completely eliminate the persisters, while levofloxacin, moxifloxacin and the combination cannot, providing a new and more effective solution for the treatment of recurrent and refractory urinary tract infections.
[0029] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1A This is a comparison diagram of the time-killing curves of the compounds of the present invention and clinical fluoroquinolone drugs against Escherichia coli UTI89 in the stationary phase;
[0031] Figure 1B It is a comparison diagram of the time killing curve of the compound against the stationary Escherichia coli UTI89 compared with the clinical fluoroquinolone drugs;
[0032] Figure 2A Comparison of the extent of biofilm formation in the evaluation of compositions for killing biofilm bacteria;
[0033] Figure 2B In the evaluation of the composition for killing biofilm bacteria, the activity of QDF and commonly used quinolone compositions in killing biofilm persisters was compared by CFU assay;
[0034] Figure 3AThis is a comparative diagram of the activity of the composition against Escherichia coli UTI89 in the bladder of a UTI mouse model;
[0035] Figure 3B This is a comparative chart of the activity of the composition against Escherichia coli UTI89 in the kidney of the UTI mouse model. DETAILED DESCRIPTION
[0036] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0037] In order to solve the deficiencies of the prior art, the present invention discloses a drug or composition for resisting persister bacteria and its use, wherein the drug comprises compound 1 to compound 8, and their chemical structural formulas are as follows:
[0038] Among them, compound 2 We named it Qingdafloxacin (QDF). The Qingdafloxacin (QDF) has excellent anti-persistent activity and is more effective than clinafloxacin.
[0039] Furthermore, the eight clinafloxacin derivatives synthesized in the present invention are Compounds 1 to 8, respectively, and their synthesis methods are as follows:
[0040] The preparation of compound 1 comprises the following steps: using 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid as a starting material, reacting with 3-(tert-butyloxycarbonylamino)pyrrolidine in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and acetonitrile to synthesize compound 1, wherein the chemical formula of compound 1 is C 16 H 17 FN4O3, relative molecular mass is 332.34;
[0041] The preparation of compound 2 comprises the following steps: using 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester as a raw material, reacting with 3-(tert-butyloxycarbonylamino)pyrrolidine in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and acetonitrile to synthesize compound 2, which is named Qingdafloxacin (QDF). The chemical formula of QDF is C 18 H 20FN3O4, relative molecular mass is 361.37;
[0042] The preparation of compound 3 comprises the following steps: using QDF as a starting material, reacting with 2-thiopheneacetyl chloride in the presence of dichloromethane (DCM) and triethylamine to synthesize compound 3, the chemical formula of which is C 24 H 24 FN3O5S, relative molecular mass is 485.53;
[0043] The preparation of compound 4 comprises the following steps: using compound 1 as a starting material, reacting with 2-thiopheneacetyl chloride in the presence of dichloromethane (DCM) and triethylamine to synthesize compound 4, the chemical formula of which is C 22 H 21 FN4O4S, relative molecular mass is 456.49;
[0044] The preparation of compound 5 comprises the following steps: using QDF as a starting material, reacting with n-butyryl chloride in the presence of dichloromethane (DCM) and triethylamine to synthesize compound 5, the chemical formula of which is C 22 H 26 FN3O5, relative molecular mass is 431.46;
[0045] The preparation of compound 6 comprises the following steps: using compound 1 as a starting material, reacting with n-butyryl chloride in the presence of dichloromethane (DCM) and triethylamine to synthesize compound 6, the chemical formula of which is C 20 H 23 FN4O4, relative molecular mass is 402.43;
[0046] The preparation of compound 7 comprises the following steps: using 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid as a starting material, reacting with 2,3-di-oxo-acetyl-5-deoxy-5-fluoro-D-cytidine in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and acetonitrile to synthesize compound 7, the chemical formula of which is C 18 H 12 F2N4O7, relative molecular mass is 434.31;
[0047] The preparation of compound 8 comprises the following steps: using 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid as a starting material, reacting with 5-fluorouracil-1-acetic acid in the presence of potassium hydroxide aqueous solution to synthesize compound 8, the chemical formula of which is C 16 H 10 F2N4O5, relative molecular mass is 376.28.
[0048] The structures of the above 8 clinafloxacin derivatives were confirmed by NMR and mass spectrometry, and calibrated by high performance liquid chromatography. The above 8 clinafloxacin derivatives were kept and preserved. Compounds 1, 2, and clinafloxacin all have a 3-aminopyrrolidine substituent at position 7; Moxifloxacin has a diazabicyclic ring; heterocyclic nitrogen rings can increase activity and affect its pharmacokinetics, such as levofloxacin containing a 4-methylpiperazine; substitution at position 8 can affect antibacterial activity. Clinafloxacin contains a chlorine substituent at position 8 of the quinolone nucleus; Moxifloxacin, gatifloxacin, compound 2, and compound 5 have a methoxy group at position 8.
[0049] The present invention also provides a composition for resisting persister bacteria, wherein the active components of the composition include any one or more of compounds 1 to 8, and also include one and / or more of levofloxacin, nitrofurantoin, and gentamicin. A preferred composition of the present invention includes quindafloxacin and gentamicin, wherein the quindafloxacin and gentamicin achieve the same blood drug concentration after administration of the composition, and the blood drug concentration is both an average of 5 μg / mL.
[0050] Further, the preferred composition also includes cindafloxacin, furantoin and gentamicin, and the active ingredients of the composition are composed of cindafloxacin, gentamicin and furantoin, and the content of cindafloxacin, furantoin and gentamicin is such that after the composition is applied, cindafloxacin, furantoin and gentamicin reach the same blood drug concentration, which is an average blood drug concentration of 5 μg / mL. The combination of QDF+gentamicin+furantoin or ceftriaxone completely eradicates all dormant bacteria containing persisters in vitro within 3 days, and eliminates biofilm bacteria within 5 days, while other compositions including moxifloxacin and levofloxacin compositions cannot completely eliminate biofilm bacteria. In addition, in a mouse model of persistent urinary tract infection, the combination of QDF+gentamicin+furantoin completely eradicates bacteria in mouse bladder and kidney tissues, while single antibiotics or other compositions currently used for the treatment of urinary tract infections fail to do this.
[0051] According to another aspect of the present invention, the present invention also provides a use of a compound having anti-persistent bacteria in the preparation of a compound capable of resisting persistent infection caused by Escherichia coli biofilm and / or Escherichia coli biofilm persisters. The above-mentioned compounds 1 to 8 and the composition composed of them are used to treat urinary tract infection caused by uropathogenic Escherichia coli, wherein the uropathogenic Escherichia coli includes persistent Escherichia coli and recurrent persistent Escherichia coli.
[0052] The present invention provides a method for treating urinary tract infection caused by uropathogenic Escherichia coli. Specifically, the method comprises the simultaneous or sequential administration of one or more selected from the following antibiotics: quindafloxacin (QDF) or a combination of QDF+gentamicin+nitrofurantoin or ceftriaxone, wherein the urinary tract infection caused by uropathogenic Escherichia coli is a persistent biofilm infection.
[0053] The present invention provides the following examples to verify the composition of the present invention.
[0054] Example
[0055] Unless otherwise specified, the materials and methods used in the embodiments of the present invention are as follows:
[0056] (1) Bacterial strains and antibiotics
[0057] E. coli UTI89 was cultured in Luria-Bertani (LB) medium with shaking at 37°C. Gatifloxacin and clarithromycin were purchased from Aladdin (Shanghai, China), and clinafloxacin, moxifloxacin, levofloxacin, gentamicin, rifampicin, ceftriaxone, nitrofurantoin, and sulfamethoxazole / trimethoprim were purchased from MacLean (Shanghai, China). Stock solutions were prepared in appropriate solvents and sterilized by filtration and used at the indicated concentrations.
[0058] (2) Synthesis of clinafloxacin derivatives
[0059] We previously found that the drug clinafloxacin, which was discontinued by the FDA, has good anti-persister activity. To identify new and more effective compounds with anti-persister activity, we synthesized 8 clinafloxacin derivatives, the target compound. Based on the existing technology, 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid was used as the starting material to prepare 1,8-diazabicycloundecane-7-ene from 3-(tert-butoxycarbonylamino)pyrrolidine and acetonitrile. Compound 2 (QDF) was synthesized from 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester. Compounds 4 and 6 were synthesized from compound 1 and 2-thiopheneacetyl chloride and acetyl chloride in the presence of dichloromethane and triethylamine, respectively. Compounds 3 and 5 were prepared from compound 2 and 2-thiopheneacetyl chloride and acetyl chloride in the presence of dichloromethane and triethylamine, respectively. Compounds 7 and 8 were synthesized by reacting 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid with 2,3-di-oxo-acetyl-5-deoxy-5-fluoro-D-cytidine and 5-fluorouracil-1-acetic acid, respectively.
[0060] (3) MIC (Minimum Inhibitory Concentration) & MBC (Minimal Bactericidal Concentration) Determination
[0061] An overnight shaking culture of E. coli UTI89 was diluted 1:100 into LB medium, and 100 μl of the diluted culture was transferred to a 96-well microtiter plate. 100 μl of the antibiotic solution was added to the first column to obtain a final concentration of 10 μg / ml of antibiotic, and then serially diluted 2-fold to 10, 5, 2.5, 1.25, 0.625, 0.3125, 0.16, 0.08, 0.04, 0 μg / ml. The plate was incubated overnight at 37°C without shaking. The MIC value was determined as the lowest concentration that inhibited visible growth. After the MIC determination, 10 μl from all wells with no visible bacterial growth was inoculated on LB agar plates and incubated at 37°C for 24 hours, and colony forming units (CFU) were counted to determine the MBC. Each sample was replicated 3 times, and each experiment was repeated 3 times.
[0062] (4) Combination bactericidal test of E. coli UTI89 in the stationary phase
[0063] Escherichia coli UTI89 strain was cultured to the stationary phase, 1 ml of the culture was distributed into 1.5 ml centrifuge tubes, and then different antibiotics and combinations (5 μg / ml) were added. On the 1st, 3rd, and 5th day, 100 μl of the bacterial suspension was taken out, washed twice with phosphate buffered saline (PBS), serially diluted 10 times, and then CFU counts were performed on LB agar plates.
[0064] (5) Microtiter plate biofilm assay
[0065] In vitro 96-well microtiter plate-based biofilm assays were performed as described previously. Briefly, an overnight shaking culture of E. coli UTI89 was diluted 1:100 into LB medium, and 100 μl samples were transferred in triplicate into a 96-well microtiter plate and then incubated at 37°C for 48 h without shaking. Planktonic cells were then removed with a pipette, and fresh LB medium and antibiotics were added to each well, and three wells without antibiotics were retained as controls. After 1, 3, and 5 days of incubation, the wells were washed twice with sterile PBS (1X), and the adherent cells were resuspended in sterile PBS using a pipette tip and serially diluted 10-fold to 10 -6. Take 10 μl of bacterial suspension and inoculate on LB agar for CFU count. Measure the survival rate of bacteria. For semi-quantitative biofilm assay, add crystal violet (150 μl, 0.1%) to the wells and incubate for 10-15 minutes, then wash twice with sterile water. The biofilm is dissolved with acetic acid (125 μl, 30%) and the absorbance at 550 nm is quantified in a microplate reader.
[0066] (6) Mouse infection model
[0067] Balb / c female mice (6-8 weeks old) were housed in a clean animal environment. Animals had access to water and standard mouse chow throughout the study. The use of animals in this study followed the guidelines and was approved by the Institutional Animal Care and Use Committee. Mouse studies were performed as described with minor modifications. Briefly, SPF-grade Balb / c mice were assigned to different treatment groups and were not provided with water one day before the experiment to prevent urination after bacterial inoculation. Mice were anesthetized with 4% chloral hydrate (10 μL / g) intraperitoneally, and then 50 μl of bacterial suspension was inoculated through the urethra with approximately 107 CFU of a 24-hour stationary culture of E. coli UTI89. Three days after infection, three mice in the control group were sacrificed, the starting CFU was determined, and antibiotic treatment was continued for 7 days. QDF (100 mg / kg / day), levofloxacin (100 mg / kg / day), and nitrofurantoin (100 mg / kg / day) were administered by oral gavage, and gentamicin (20 mg / kg / day) was administered by intraperitoneal injection every day for 7 days. Drug-free control mice were given water by oral gavage. Mice were sacrificed 3 days after 7 days of antibiotic treatment to allow any relapse to occur. Kidneys and bladders were harvested under sterile conditions, homogenized and diluted in PBS, and bacterial titers were determined by serial dilutions of tissue homogenates on LB plates.
[0068] Example 1
[0069] The activity of 8 clinafloxacin derivatives and some clinical compounds synthesized in this application on Escherichia coli UTI89 strain was tested. The MIC and MBC values of the above compounds and control drugs are shown in Table 1. Compared with other clinical drugs, the MIC (minimum concentration to inhibit visible growth) and MBC of compounds 1 and 2 have good antibacterial and bactericidal activity against Escherichia coli UTI89, with MIC <0.04 mg / ml and MBC of 0.08-0.16 mg / ml. Compound 5 also has certain antibacterial activity, with a MIC of 0.625-1.25 μg / ml and an MBC of 2.5-5 μg / ml, while other synthetic compounds have lower activity. The antibacterial activity of compounds 1 and 2 is similar to that of Gatifloxacin and Clinafloxacin, and the MIC is lower than that of levofloxacin and moxifloxacin.
[0070] Table 1. MIC and MBC of the newly synthesized clinafloxacin derivatives and control drugs against E. coli UTI89
[0071]
[0072] Example 2
[0073] We compared the activities of the eight clinafloxacin derivatives synthesized by the present invention with those of fluoroquinolone antibiotics at the same concentration of 50 μM against stationary E. coli UTI89. We treated stationary E. coli with antibiotics and counted CFU at different times (0, 1, 3, and 5 days) to compare their bactericidal activities. Figure 1A As shown, compound 2 (QDF) had the highest activity against stationary E. coli UTI89. Both QDF and clinafloxacin completely eliminated stationary E. coli within 5 days, while moxifloxacin did not kill all bacteria within 5 days. Levofloxacin had relatively poor activity against stationary E. coli, so that about 104 bacteria remained after 5 days of drug exposure. In addition, compounds 1 and 5 had moderate activity, while compounds 4, 6, 7, and 8 had poor activity against stationary E. coli UTI89.
[0074] Example 3
[0075] To more effectively eradicate E. coli UTI89 persisters, we evaluated a combination of clinical drugs, including the commonly used quinolone drugs moxifloxacin, clinafloxacin, or levofloxacin and QDF at a concentration of 5 μg / mL, which is close to the Cmax (maximum blood drug concentration) of most clinical drugs. Figure 1BThe results shown indicate that the combination of QDF + gentamicin + ceftriaxone / nitrofurantoin was the best among the combinations of moxifloxacin, clinafloxacin or levofloxacin, and completely eradicated all stationary E. coli UTI89, including persisters, within 3 days; the combination of moxifloxacin + gentamicin + ceftriaxone was less effective, eradicating stationary E. coli within 5 days, indicating that the QDF combination had stronger activity in eradicating stationary E. coli UTI89 than the combination of levofloxacin, moxifloxacin or clinafloxacin.
[0076] The above results indicate that some of the combinations of the three drugs have a strong ability to eradicate stationary E. coli UTI89. To identify effective combinations that can eradicate biofilm bacteria, we tested various combinations by using drugs for growing bacteria and drugs for non-growing persisters and analyzed the results by crystal violet staining ( Figure 2A ) and CFU counts ( Figure 2B ) to evaluate their effects. Although the crystal violet staining assay is not completely quantitative because it does not distinguish the effects of different drug treatments, Figure 2A The results shown can indicate that QDF + gentamicin + ceftriaxone and QDF + gentamicin + nitrofurantoin are superior to other quinolone combinations; Figure 2B The results shown show that single-agent QDF, Clinafloxacin, moxifloxacin, levofloxacin, or a combination of the two agents failed to eradicate all biofilm bacteria in a more quantitative CFU assay; importantly, only the two three-drug combinations of QDF + gentamicin + ceftriaxone and Clina + gentamicin + nitrofurantoin completely eradicated all biofilm bacteria within 5 days, while the levofloxacin or moxifloxacin three-drug combinations failed to do so.
[0077] Example 4
[0078] Our in vitro results above show that the combination of three drugs is more effective than two drugs or a single drug. To further confirm the bactericidal ability of the in vitro effective composition in vivo, we evaluated the composition in Balb / c mice infected with Escherichia coli UTI89 bacteria (mouse infection model). To establish persistent infection, infection lasted for 3 days in the mouse UTI model and then treated with QDF, levofloxacin, nitrofurantoin, gentamicin and their effective compositions according to the above in vitro studies. QDF (100 mg / kg / day), levofloxacin (100 mg / kg / day) and nitrofurantoin (100 mg / kg / day) were administered by oral gavage, and gentamicin (20 mg / kg / day) was administered by intraperitoneal injection every day for 7 days. No drug control mice were given water by oral gavage. Mice were sacrificed 3 days after 7 days of antibiotic treatment to allow any relapse to occur. Kidneys and bladders were harvested under sterile conditions, homogenized and diluted in PBS, and bacterial titers were determined by serial dilution of tissue homogenates on LB plates. Treatments were given daily for 7 days as described above, followed by a 3-day waiting period after treatment to allow for any possible relapses before the mice were sacrificed for CFU counts, which analyzed the number of bacteria in the bladder and kidneys of the mice. Figure 3A and 3B As shown, bacterial titers in all antibiotic-treated groups were lower than those in the untreated control group, and the triple-drug combination therapy was significantly superior to the corresponding single-drug treatment. The procedure for testing the activity of drug combinations against E. coli UTI89 in the UTI mouse model was as follows: mice were infected with E. coli UTI89 bacteria (107 CFU) via the transurethral route, and the infection was established for 3 days before antibiotic treatment. Treatment groups were treated with drugs daily for 7 days, while negative control (NC) mice were given water by gavage. Mice were sacrificed 3 days after the final antibiotic treatment, and whole bladder and kidney homogenates were serially diluted for CFU counts on LB plates. According to Figure 3A The data comparison results shown show that the combination of QDF+gentamicin+nitrofurantoin and QDF+gentamicin can completely eradicate all bacteria in the bladder. Figure 3B The data comparison results shown show that the combination of QDF+gentamicin+nitrofurantoin and QDF+gentamicin can also completely eradicate all bacteria in the kidneys; the in vivo research results show that the bactericidal effect of the QDF combination on persistent bacteria is not only true in vitro, but also in the persistent UTI mouse model.
[0079] In our previous studies, we found that the fluoroquinolone clinafloxacin has unique antipersister activity against S. aureus and Pseudomonas aeruginosa in vitro. In this study, we made a series of new clinafloxacin derivatives and found that QDF has excellent activity against growing and non-growing stationary E. coli UTI89. We determined that the highly active combination QDF + gentamicin + ceftriaxone or nitrofurantoin can completely eradicate the biofilm form of E. coli UTI89 in vitro, while current UTI treatment drugs, including nitrofurantoin, gentamicin and levofloxacin or their combination, cannot do so. Most importantly, we found that the combination of QDF + gentamicin + nitrofurantoin completely eradicated the bacteria in a mouse model of persistent infection with UTI, while current drugs used clinically to treat urinary tract infections, such as levofloxacin, nitrofurantoin, gentamicin or their combination, failed to do so.
[0080] Notably, previous studies have shown that current antibiotic treatments for UTIs fail to eradicate persistent UPEC bacteria in vitro and in vivo. Although combining the persister drug polymyxin with nitrofurantoin or levofloxacin showed superior bactericidal results, where nearly all bacteria in infected bladders or kidneys were eradicated, some bacteria could occasionally be cultured from the treated organs. To our knowledge, the finding that the QDF+gentamicin+nitrofurantoin combination completely eradicated all bacteria in infected organs is the first time that a persister combination has achieved this promising result in a mouse model of persistent UTI infection.
[0081] During the synthesis of the new compounds, we retained the 3-aminopyrrolidine substituent at position 7, as it improves the bactericidal ability of clinafloxacin. In addition, 3-aminopyrrolidine has been reported to significantly enhance the in vitro and in vivo activities of other site groups, and this relative difference in antibacterial potency is independent of the known antigyrase activity of common fluoroquinolones. This may be one of the reasons for the strong bactericidal potency and high antipersister activity of QDF. Quinolones are placed at position 8, which can lead to major changes in pharmacodynamics. In addition, the methoxy group at position 7 of QDF is structurally identical to moxifloxacin, which can not only reduce the phototoxicity of QDF relative to clinafloxacin but also improve its antipersister activity. It has been reported that the 8-methoxy-substituted compounds have stronger activities against mutant gyrase and wild-type topoisomerase IV compared with ciprofloxacin. Therefore, we synthesized clinafloxacin derivatives with 8-methoxy substitution and identified QDF as the best candidate for killing persisters in this study.
[0082] In conclusion, we have identified a more potent clinafloxacin derivative, QDF, and found several QDF compositions that can eradicate persisters, including biofilm bacteria, in vitro and in mouse models. In addition, we found that compared with levofloxacin, QDF preferentially downregulated glutamate decarboxylase and glutaminase, glutathione anabolism, methane metabolism, affected the tricarboxylic acid cycle, downregulated ribosomal genes, pyrimidine metabolism genes, starvation stress genes, as well as membrane permeability genes and efflux genes, which may jointly impair stress response, acid resistance, and DNA repair, leading to more severe DNA damage, which may be the mechanism of QDF's unique anti-persister activity. Further studies are needed to evaluate QDF as a promising novel anti-persister drug candidate for more effective treatment of recurrent UTIs in the future.
[0083] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A composition having anti-persistent bacteria and biofilm bacteria, characterized in that: The composition is and gentamicin.
2. The composition according to claim 1, characterized in that Said and gentamicin in an amount such that after administration of the composition, and gentamicin to achieve the same blood concentration.
3. A composition having anti-persistent bacteria and biofilm bacteria, characterized in that: The composition is Nitrofurantoin and gentamicin.
4. The composition according to claim 3, characterized in that Said The amount of nitrofurantoin and gentamicin is such that after administration of the composition Nitrofurantoin and gentamicin achieve similar plasma concentrations.
5. A composition having anti-persistent bacteria and biofilm bacteria properties, characterized in that: The composition is Ceftriaxone and gentamicin.
6. The composition according to claim 5, characterized in that Said The content of ceftriaxone and gentamicin is such that after administration of the composition Ceftriaxone and gentamicin achieved similar blood concentrations.
7. Use of a composition having resistance to persister bacteria and biofilm bacteria in the preparation of a drug capable of resisting persistent infection caused by Escherichia coli biofilm and / or persister bacteria of Escherichia coli biofilm, characterized in that: The composition comprises the composition of any one of claims 1-6.
8. The use according to claim 7, characterized in that The composition is used for treating urinary tract infection caused by uropathogenic Escherichia coli.
9. The use according to claim 8, characterized in that The urinary tract infections include recurrent and refractory urinary tract infections, as well as chronic persistent infections and biofilm infections caused by other Escherichia coli.
